modelC05BA53
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | HeparinCombinations | |
| ATC code: | C05BA53 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 5000 | mg |
| volume of distribution: | 0.07 | L |
| clearance: | 0.015 | L/kg/h |
| other parameters in model implementation | ||
Heparin, in combination preparations, is an anticoagulant used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. It acts by potentiating the activity of antithrombin III, thereby inhibiting the formation of fibrin clots. This drug is typically administered parenterally due to poor oral bioavailability and is used in both inpatient and outpatient settings. Heparin combinations may contain local anesthetics or other agents. Heparin and its combinations remain approved and widely used today.
Pharmacokinetics
Estimated pharmacokinetic parameters for typical adult patients receiving heparin combination preparations; no specific publication found for C05BA53 combination products.
References
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Hermiz, J, et al., & Toquica Gahona, C (2025). Apixaban Failure in A Post-Bariatric Surgery Female Patient with Thoracic Aortic Thrombus Secondary to Covid-19. European journal of case reports in internal medicine 12(4) 005254–None. DOI:10.12890/2025_005254 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40270670
Laham, RJ, et al., & Simons, M (1999). Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug metabolism and disposition: the biological fate of chemicals 27(7) 821–826. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10383927
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)